1[1]Kim NW, Piatyszek MA, Prowse KR, et al. Specific associa tion of human telomerase activity with immortal cells and cancer. Science, 1994, 266(5193): 2011～2015 被引量：1
2[2]Kim NW. Clinical implications of telomerase in cancer. Eur J Cancer, 1997, 33(5):781～786 被引量：1
3[3]Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer, 1997, 33(5): 787～791 被引量：1
4[4]Yoshida K, Sugino T, Tahara H, et al. Telomerase activity in bladder carcinoma and its implication for noninvasive diagno sis by detection of exfoliated cancer cells in urine. Cancer, 1997, 79(2):362～369 被引量：1
5[5]Yoshida K, Sugino T, Goodison S, et al. Detection of telom erase activity in exfoliated cancer cells in colonic luminal washings and its related clinical implications. Br J Cancer, 1997, 75(4):548～553 被引量：1
6[6]Kyo S, Takakura M, Ishilcowa H, et al. Application of telomerase assay for the screening of cervical lesions. Cancer Res, 1997, 57(10): 1863～1867 被引量：1
7[7]Mu XC, Brien TP, Ross JS, et al. Telomerase activity in be nign and malignant cytologic fluids. Cancer, 1999,87(2):93～99 被引量：1
8[8]Toshima S, Arai T, Yasuda Y, et al. Cytological diagnostic and telomerase activity of cells in effusions of body cavities. Oncol Rep, 1999, 6(1):199～203 被引量：1
9[9]Yang CT, Lee MH, Lan RS, et al. Telomerase activity in pleural effusions: diagnostic significance. J Clin Oncol, 1998,16 (2):567～573 被引量：1
10[10]Tangkijvanich P, Tresukosol D, Sampatanukul P, et al. Telomerase assay for differentiating between malignancy-related and nonmalignant ascites. Clin Cancer Res, 1999, 5(9): 2470～2475 被引量：1
7Queiroz c, Barral-Netto M, Bacchi CE. Characterizing subpopulations of neoplastic cells in serous effusions. The role of immunocytochemistry. Acta Cvtol 2001; 45:18-22 被引量：1
8Krishan A, Ganjei-Azar P, Jorda M, Hamelik RM, Reis IM, Nadji M. Detection of tumor cells in body cavity fluids by flow cytornetric and immunocytochemical analysis. Diagn Cytopathol 2006; 34:528-541 被引量：1
10Porcel JM, Vives M, Esquerda A, Salud A, Perez B, Rodriguez-Panadero F. Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions. Chest 2004; 126:1757-1763 被引量：1
